In this study, CD137 agonist when given IgG2a-Fc function targeting CD137+Tregs, clearly decreased total Treg numbers and maintained CD8+T cell numbers,which effectively enhanced the anti-tumor immune response. Here, TNFRSF9 is linked to neoplasm.